Courtney DiNardo, MD
Enriched profileProfessor, Department of Leukemia, Division of Cancer Medicine · The University of Texas MD Anderson Cancer Center
Courtney DiNardo is Professor, Department of Leukemia, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center. OpenAlex indexes 1,656 publications with 49,719 citations (h-index 96); ClinicalTrials.gov lists 24 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Hematology / Oncology profiles in the findmyKOL directory. Clarivate lists Courtney DiNardo as a Highly Cited Researcher (Clinical Medicine, 2021-2024).
Data verified 25 Aug 2026
Overview
Updated 27 Aug 2026
Courtney D. DiNardo, MD, is Professor, Department of Leukemia, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, Houston, TX. The public record shows 1,656 publications with 49,719 citations (h-index 96), centered on Acute Myeloid Leukemia Research, Chronic Myeloid Leukemia Treatments, Myeloproliferative Neoplasms: Diagnosis and Treatment. It also documents an investigator role on 24 registered clinical trials, industry payments reported by 32 companies, 4 NIH-funded awards (2021–2026).
- Most recent indexed publication: 2026 · Blood advances
- Top research focus: Acute Myeloid Leukemia Research
- 24 registered trials on ClinicalTrials.gov
- Open Payments reporting from 32 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 284 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 519.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 24 registered studies on ClinicalTrials.gov. The most recent:
- Phase 1/1b Trial Of Olutasidenib And Ziftomenib For NPM1 And IDH1 Co-Mutated Acute Myeloid Leukemia
Sponsor: M.D. Anderson Cancer Center
- Evaluate the Safety, Tolerability, Pharmacokinetic Profile, Efficacy of Bl-M11D1
Sponsor: SystImmune Inc.
Industry payments
Updated 27 Aug 2026
32 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- ABBVIE INC.Program year20255 payments$11,465openpaymentsdata.cms.gov ↗
- Rigel Pharmaceuticals, Inc.Program year20256 payments
- Genmab A/SProgram year20251 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
67.5%Nucleoside Metabolic Inhibitor16%Inqovi100%Part D<11 patientsIsocitrate Dehydrogenase 1 Inhibitor15.4%Tibsovo100%Part D<11 patientsAnti-infectives
32.5%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor18.9%Valacyclovir100%Part D≥18 patientsFluoroquinolone Antibacterial13.6%Levofloxacin100%Part D≥14 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 27 Aug 2026
4 NIH research awards on record, funded 2021–2026 per NIH RePORTER. The latest:
- Role of targeting ATPases BRG1/BRM in therapy of AML
University of Tx Md Anderson Can Ctr
FY2026$542,663R01CA291918 - T32 Research Training in Academic Medical Oncology
University of Tx Md Anderson Can Ctr
FY2026$393,627T32CA009666 - Role of targeting ATPases BRG1/BRM in therapy of AML
University of Tx Md Anderson Can Ctr
FY2025$542,663R01CA291918
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.
Journal of clinical oncology
Article2026 - Integrated Analysis of Genomics, Molecular Responses, and Outcomes of CBF-AML with FLAG-Based Therapy on a Phase II Trial.
Blood cancer discovery
Clinical Trial2026
Most-cited works
by citation count (OpenAlex)Network
Updated 27 Aug 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/courtney-dinardo-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - ResearchGate
researchgate.net/profile/Courtney-Dinardo-2
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗
Mentions by others
where others cite or feature them- Instagram
instagram.com/runx1research/p/C90COY-qPKm
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →instagram.com ↗ - LinkedIn
linkedin.com/posts/aacrjournals_courtney-d-dinardo-md-msce-recipient-activity-7364318192967548930-vOtl
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗ - LinkedIn
linkedin.com/posts/blood-cancers-today_courtney-dinardo-discusses-first-in-human-activity-7054209342576738305-1sDh
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
Editorial & leadership roles
journal and society appointments- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
Highly Cited Researcher
Clarivate's annual list, by award category and year- Clinical Medicine2021202220232024verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →clarivate.com ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →aacr.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
Secondary affiliations
appointments beyond the home institution- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- Associate Member
The University of Texas MD Anderson UTHealth Graduate School of Biomedical Sciences
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗ - Leader
Hereditary Hematologic Malignancy Clinic (HHMC), MD Anderson (exact formal title uncertain -- AAMDSIF source describes her as having 'led to the development of' HHMC without stating a formal title …
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →aamds.org ↗
Media & interviews
press, podcasts and appearances- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ascopost.com ↗
- Karger Fast Facts Oncology podcast
Season 4 Episode 3 - "Courtney DiNardo, MD MSCE: Perspectives on AML"
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →podcasts.apple.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Hagop Kantarjian, MD
The University of Texas MD Anderson Cancer Center
Gabriel Hortobagyi, MD
The University of Texas MD Anderson Cancer Center
Jaffer Ajani, MD
The University of Texas MD Anderson Cancer Center
Funda Meric-Bernstam, MD
The University of Texas MD Anderson Cancer Center